BACKGROUND: Bryostatin 1 is a marine derived macrolactone with antineoplastic activity modulated through protein kinase C, and with good activity in in vitro and in vivo models. There are few drugs that offer palliation for metastatic soft-tissue sarcoma and head and neck cancer, and drugs with new mechanisms of action warrant detailed disease specific study. PATIENTS AND METHODS: Two phase II studies for patients with incurable soft tissue sarcoma (12), or head and neck cancer (12) were conducted. Patients were treated with bryostatin, 120 mg/m2/72 hours every 2 weeks for 3 cycles prior to re-evaluation. Most patients had received prior chemotherapy. RESULTS: No patients had objective responses to therapy. Six patients had brief periods of disease stabilization. Toxicity was generally mild, with myalgia being prominent (n=8). Hyponatremia, not previously described, occurred in 5 patients. The mechanism of this toxicity was unclear. CONCLUSIONS: Bryosytatin 1 given as a single agent for advanced adult soft tissue sarcoma and head and neck cancer is inactive. Myalgia and hyponatremia were the predominant toxicities.
BACKGROUND:Bryostatin 1 is a marine derived macrolactone with antineoplastic activity modulated through protein kinase C, and with good activity in in vitro and in vivo models. There are few drugs that offer palliation for metastatic soft-tissue sarcoma and head and neck cancer, and drugs with new mechanisms of action warrant detailed disease specific study. PATIENTS AND METHODS: Two phase II studies for patients with incurable soft tissue sarcoma (12), or head and neck cancer (12) were conducted. Patients were treated with bryostatin, 120 mg/m2/72 hours every 2 weeks for 3 cycles prior to re-evaluation. Most patients had received prior chemotherapy. RESULTS: No patients had objective responses to therapy. Six patients had brief periods of disease stabilization. Toxicity was generally mild, with myalgia being prominent (n=8). Hyponatremia, not previously described, occurred in 5 patients. The mechanism of this toxicity was unclear. CONCLUSIONS: Bryosytatin 1 given as a single agent for advanced adult soft tissue sarcoma and head and neck cancer is inactive. Myalgia and hyponatremia were the predominant toxicities.
Authors: S Weitman; A M Langevin; R L Berkow; P J Thomas; C A Hurwitz; A S Kraft; R L Dubowy; D L Smith; M Bernstein Journal: Clin Cancer Res Date: 1999-09 Impact factor: 12.531
Authors: M L Varterasian; R M Mohammad; D S Eilender; K Hulburd; D H Rodriguez; P A Pemberton; J M Pluda; M D Dan; G R Pettit; B D Chen; A M Al-Katib Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: P A Philip; D Rea; P Thavasu; J Carmichael; N S Stuart; H Rockett; D C Talbot; T Ganesan; G R Pettit; F Balkwill Journal: J Natl Cancer Inst Date: 1993-11-17 Impact factor: 13.506
Authors: D J Propper; V Macaulay; K J O'Byrne; J P Braybrooke; S M Wilner; T S Ganesan; D C Talbot; A L Harris Journal: Br J Cancer Date: 1998-11 Impact factor: 7.640
Authors: G C Jayson; D Crowther; J Prendiville; A T McGown; C Scheid; P Stern; R Young; P Brenchley; J Chang; S Owens Journal: Br J Cancer Date: 1995-08 Impact factor: 7.640
Authors: S Madhusudan; A Protheroe; D Propper; C Han; P Corrie; H Earl; B Hancock; P Vasey; A Turner; F Balkwill; S Hoare; A L Harris Journal: Br J Cancer Date: 2003-10-20 Impact factor: 7.640
Authors: Muskan Floren; Sebastian Restrepo Cruz; Christina M Termini; Kristopher D Marjon; Keith A Lidke; Jennifer M Gillette Journal: Oncogene Date: 2020-03-19 Impact factor: 9.867